Introduction
============

Paclitaxel, one of the most widely used cytotoxic agents, induces mitotic arrest and apoptosis in proliferating cells by targeting tubulin, a component of the mitotic spindle ([@b24-ijn-1-375]; [@b5-ijn-1-375]). Like other small, hydrophobic agents, paclitaxel binds extensively to plasma proteins, and its pharmacokinetic profile is characterized by a short plasma elimination half-life with a broad tissue distribution ([@b19-ijn-1-375]; [@b46-ijn-1-375]). These unfavorable pharmacokinetic characteristics are associated with limited tumor and high systemic tissue exposure, thus reducing the therapeutic index of paclitaxel. In addition, the intravenous administration of hydrophobic agents requires the use of solubilizing agents, such as Cremophor^®^ EL/ethanol. Cremophor EL is a biologically and pharmacologically active compound, and its use is associated with acute hypersensitivity reactions ([@b14-ijn-1-375]).

As a chemotherapeutic agent, paclitaxel is indicated for first-line platinum-based combination treatment in advanced ovarian carcinoma and non-small cell lung carcinoma (NSCLC). Paclitaxel is also indicated for second-line treatment of ovarian and breast carcinoma. The toxicity profile of paclitaxel is characterized by bone marrow suppression, neuropathy, and alopecia ([@b40-ijn-1-375]). Hematological toxicities can be managed with the prophylactic use of hematopoietic growth factors, particularly in patients at risk for myelosuppression ([@b25-ijn-1-375]). Also patients require pretreatment corticosteroids and anti-histamines to prevent acute hypersensitivity reactions. The administration of paclitaxel typically requires a 3-hour infusion, on a 3-week schedule. Weekly taxane schedules are currently being investigated, as more frequent administration at a lower dose may reduce myelosuppression and febrile neutropenia ([@b42-ijn-1-375]).

Biodegradable, macromolecular polymer--drug conjugates allow for a more sustained and targeted delivery of chemotherapeutic agents. The performance of these nano-sized (5--100 nm) polymer-based pharmaceuticals is influenced by morphological characteristics, surface chemistry, and molecular weight ([@b21-ijn-1-375]; [@b3-ijn-1-375]). When well-designed, these polymer--drug conjugates preferentially deliver active drug to tumor tissue, limiting exposure of normal tissues. In addition, the slow release of drug from the polymer yields lowers peak plasma concentrations of active drug. Paclitaxel poliglumex, a polymer--drug conjugate of paclitaxel and poly-L-glutamic acid, was designed to enhance the therapeutic index of paclitaxel by improving its pharmacokinetic profile, and to provide a water-soluble alternative to the standard paclitaxel formulation.

Paclitaxel poliglumex
=====================

A macromolecular polymer-drug conjugate
---------------------------------------

Paclitaxel poliglumex (PPX) is a polymer--drug conjugate that links paclitaxel to a biodegradable polymeric backbone consisting of L-glutamic acid residues ([@b44-ijn-1-375]). Paclitaxel is conjugated by ester linkage to the γ-carboxylic acid side chains of poly-L-glutamic acid. Because the conjugation site is through the 2′ hydroxyl of paclitaxel, a site crucial for tubulin binding, conjugated paclitaxel does not interact with β-tubulin and is biologically inactive ([@b17-ijn-1-375]). The median molecular weight of PPX is 38.5 kDa. Conjugated paclitaxel represents approximately 36% by weight of PPX, equivalent to about one paclitaxel ester linkage per 11 glutamic acid units ([Figure 1](#f1-ijn-1-375){ref-type="fig"}).

The rate of release of paclitaxel from PPX by hydrolysis in buffered saline solution and in mouse or human plasma was evaluated. Incubation of PPX in buffered saline or plasma for 24 hours at 37°C showed that less than 14% of the bound paclitaxel had been hydrolyzed. This indicates that PPX is relatively resistant to plasma esterases and is unlikely to release substantial amounts of paclitaxel in the circulation, even with prolonged clearance times.

The characteristics of PPX were evaluated using gel-permeation chromatography in an organic mobile phase. When combined with multiple angle laser-light scattering and reflective index detection, the elution profile provides information on the apparent average molecular weight and polydispersity of the polymer. Nuclear magnetic spectroscopy confirmed the conjugation of paclitaxel to the γ and α positions of polyglutamate. Spectral changes were consistent with conjugation through the paclitaxel 2′- position with additional minor amounts of conjugation in the 7′-position. The distribution of paclitaxel on the polyglutamate backbone was studied through limited proteolysis of PPX with pronase. The resulting peptide mixtures were analyzed by reverse-phase HPLC and mass spectrometry. A wide range of peptide species were observed in the enzyme digest; they can be described as (Glu)~n~-(paclitaxel)~x~, where n = 1--20 and x = 1--6. This is in good agreement with a distribution of paclitaxel that would be expected if the conjugation occurred in a non-directed fashion ([@b44-ijn-1-375]).

Tumor accumulation
------------------

Polymer--drug conjugates passively accumulate in tumor tissue by taking advantage of the hyperpermeable tumor vasculature and reduced lymphatic clearance, a phenomenon known as the enhanced permeation and retention (EPR) effect. Tumor vasculature is more permeable to macromolecules than normal vasculature because of structural differences between the neovasculature in tumors and the mature vasculature in normal organs ([@b15-ijn-1-375]; [@b37-ijn-1-375]). The paucity of lymphatic vessels in tumor tissue allows the retention of these macromolecules in the interstitial space, resulting in a 10- to 100-fold increase in intra-tumoral drug concentrations when compared with an equivalent dose of the drug given conventionally ([@b29-ijn-1-375]; [@b16-ijn-1-375]). Macromolecules, characterized by high molecular weight, cannot be internalized into cells by simple diffusion; instead, macromolecules enter cells through endocytosis. Following internalization through endocytosis, polymer--drug conjugates are transported via the endosomal compartment to the lysosomes. Active drug is released through degradation by lysosomal enzymes, followed by diffusion of the active agent into the cytoplasm or nucleus ([Figure 2](#f2-ijn-1-375){ref-type="fig"}) ([@b10-ijn-1-375], [@b11-ijn-1-375]).

To take advantage of the EPR effect, macromolecules have to remain in circulation for at least 6 hours ([@b29-ijn-1-375]). Clinical plasma pharmacokinetics of PPX show a biphasic decline with a prolonged distribution phase, and an elimination phase with a long terminal half-life. Following a 10- to 30-minute infusion of single-agent PPX, plasma concentrations of conjugated taxanes decline biphasically ([Figure 3A](#f3A-ijn-1-375){ref-type="fig"}). The distribution phase is prolonged and the elimination phase, which appears approximately 48 hours after drug administration, is characterized by a long terminal half-life, t~1/2,z~, of 108--261.5 hours ([@b4-ijn-1-375]). PPX is relatively stable in circulation; the area under the curve (AUC) of unconjugated paclitaxel is 1%--2% of the AUC of conjugated paclitaxel. The total systemic exposure to unconjugated paclitaxel is similar after administration of equivalent doses of PPX and standard paclitaxel; however, the C~max~ values for paclitaxel are significantly lower in patients treated with PPX ([Figure 3B](#f3B-ijn-1-375){ref-type="fig"}).

The prolonged circulation time of PPX facilitates tumor accumulation through the EPR effect, as was demonstrated in model animals ([@b44-ijn-1-375]). To determine the pharmacokinetic profile of PPX and its tissue distribution, female mice with subcutaneous B16 murine melanomas were given equivalent doses of tritium-labeled paclitaxel 40 mg/ kg iv, either as \[^3^H\]paclitaxel in Cremophor EL/ethanol or as \[^3^H\]paclitaxel poliglumex in phosphate buffer. Tumor samples were collected at regular intervals up to 144 hours after the injection, and the concentrations of PPX and paclitaxel were determined by LC/MS analysis. Tumor exposure of B16 melanomas to total taxanes was increased by a factor of 3 (C~max~) or factor of 12 (AUC) in mice treated with \[^3^H\]PPX compared with animals treated with \[^3^H\]paclitaxel ([Table 1](#t1-ijn-1-375){ref-type="table"}; [Figure 4](#f4-ijn-1-375){ref-type="fig"}). Distribution of paclitaxel to the tumor was faster with \[^3^H\]paclitaxel, but overall tumor exposure to paclitaxel, with steady concentrations between 24 and 120 hours, was higher after administration of \[^3^H\]PPX. In addition to tumor tissue, PPX also accumulates in tissues with abundant reticular endothelial systems through active phagocytosis (eg, liver, spleen).

Metabolism
----------

Anti-tumor activity requires the release of paclitaxel from the conjugate through the proteolysis of the polymeric backbone. Initially, two PPX metabolites, monoglutamyl-paclitaxel isomers Glu-2′-TXL (2′-\[L-γ-glutamyl\]-paclitaxel) and Glu-7′-TXL (7′-\[L-γ-glutamyl\]-paclitaxel), were identified in tumor tissue from B16 tumor-bearing mice exposed to \[^3^H\]-labeled PPX. Subsequent pharmacokinetic analysis indicated a gradual increase of \[^3^H\]-labeled PPX metabolites in tumor tissue, reaching T~max~ at 72 hours post-administration. In comparison, administration of \[^3^H\]-paclitaxel resulted in a T~max~ at 1.5 hours. The gradual accumulation of PPX in tumor tissue was associated with prolonged tumor exposure to PPX metabolites Glu-2′-TXL and paclitaxel. These observations demonstrate the intra-tumoral degradation of the poliglutamate backbone of PPX in association with the release of paclitaxel ([@b44-ijn-1-375]).

PPX biodegradation was further characterized in vitro and in vivo using qualitative and quantitative LC/MS analysis ([@b43-ijn-1-375]). The intracellular, time-dependent generation of 5 PPX metabolites was observed in RAW 264.7 monocytes as well as the human HT-29 colon adenocarcinoma and NCI-H460 non-small lung carcinoma cell lines. In cell-free assays, mainly the carboxy exopeptidases, cathepsin B and X, could mediate PPX metabolism. In vitro, the release of conjugated paclitaxel was dependent on the activity of cathepsin B. Data from a cathepsin B deficient animal model confirmed that cathepsin B is an important in vivo mediator of PPX metabolism and the subsequent release of paclitaxel; however, other proteolytic pathways may contribute as well.

In normal physiological conditions, cathepsin B expression and activity is tightly regulated ([@b52-ijn-1-375]). In malignant tumors and premalignant lesions, cathepsin B expression is increased, which may also be associated with secretion and localization at the cell membrane ([@b35-ijn-1-375]; [@b47-ijn-1-375]; [@b22-ijn-1-375]). Both intra-cellular and membrane-bound cathepsin B contributes to the degradation of the extracellular matrix, a crucial step in the process of tumor cell invasion ([@b49-ijn-1-375]; [@b36-ijn-1-375]).

Clinical development
====================

Performance status (PS) measures the impact of tumor-related symptoms and co-morbidities, such as co-existing illnesses and older age, on a patient's functional status; poor PS is defined by a score of 2 or more on the Eastern Cooperative Oncology Group ECOG performance scale. In NSCLC, poor PS is associated with a poor prognosis and an increased vulnerability to chemotherapy-related toxicities ([@b48-ijn-1-375]; [@b8-ijn-1-375]). In the absence of clinical trials enrolling significant numbers of poor PS patients, no standard of care has been established for the treatment of patients with advanced NSCLC and poor PS. When considering treatment options for patients with advanced NSCLC and poor PS, meaningful clinical benefit is not only determined by improved survival, but also symptom relief and tolerability ([@b6-ijn-1-375]). Two phase III studies evaluated the efficacy and safety of PPX in chemotherapy-naïve patients with advanced NSCLC and a poor performance status. In STELLAR 3, PPX in combination with carboplatin was compared with paclitaxel in combination with carboplatin, and in STELLAR 4, PPX as a single agent was compared with physician's choice of either gemcitabine or vinorelbine. A third phase III study, STELLAR 2, compared PPX with docetaxel in patients with relapsed/refractory NSCLC. The primary efficacy endpoint for all three trials was survival, and PPX was shown to be as effective as current treatment options in NSCLC ([Table 2](#t2-ijn-1-375){ref-type="table"}).

Compared with docetaxel, PPX was associated with a favorable hematological toxicity profile, reducing the incidence of severe neutropenia and infection ([Table 3](#t3-ijn-1-375){ref-type="table"}). The reduced hematologic toxicity was clinically relevant as patients in the PPX arm showed a significant decrease in the requirement for supportive care ([Figure 5](#f5-ijn-1-375){ref-type="fig"}). The non-hematologic toxicity profile of PPX is characterized by minimal hair loss, a distressing side-effect of chemotherapy associated with a lowered self-esteem and a negative body image. In general, PPX-related non-hematologic severe (grade 3 or 4) adverse events are similar to those of other taxanes, with dose-related neuropathy as the most clinically important issue ([@b20-ijn-1-375]; [@b30-ijn-1-375], [@b31-ijn-1-375]).

Future directions
=================

In the phase III studies, chemo-naïve patients receiving PPX had similar overall survival compared with patients in the control arms. However, in STELLAR 4, a trend towards improved survival was noted for female patients receiving PPX compared with female patients in the control arm: 49 women received PPX and 56 received gemcitabine or vinorelbine; the median survival for females in the PPX arm was 312 days compared with 209 days for females in the control arm (log rank p = 0.069; hazard ratio = 0.65). In contrast, survival was similar for male patients, regardless of treatment, indicating a potential gender-specific benefit associated with PPX for the treatment of lung cancer ([@b39-ijn-1-375]).

The comparison of lung tumors from male and female patients has identified various tumor characteristics that may affect tumor etiology in a gender-specific manner ([@b32-ijn-1-375]; [@b50-ijn-1-375]). Particularly, lung tumorigenesis may be modulated depending on exposure to estrogen. An epidemiologic link between estrogen exposure and incidence of NSCLC has been suggested in Japanese non-smoking women ([@b23-ijn-1-375]). Younger, presumably pre-menopausal, women appear to have shorter survival than older women: in an analysis of patients with advanced NSCLC enrolled in Southwest Oncology Group (SWOG) trials, women over 70 had a 34% 1-year survival compared with 11% for those under 45 ([@b2-ijn-1-375]).

Estrogen-induced cell proliferation is a critical step in the etiology and progression of a variety of tumor types ([@b9-ijn-1-375]). The cellular response to estrogen is mediated by estrogen receptor alpha (ER-alpha) and ER-beta. These receptor proteins function as ligand-dependent transcription factors and regulate the expression of genes implicated in cell cycle control, signal transduction, and cell survival ([@b13-ijn-1-375]; [@b12-ijn-1-375]). In animal models, estrogen plays a role in normal pulmonary physiology ([@b26-ijn-1-375], [@b27-ijn-1-375]); adult females have a larger number of alveoli that are smaller in size, than males. This difference develops as animals reach sexual maturity and seems to be mediated mainly by estrogens ([@b28-ijn-1-375]). In vivo studies show that ER-beta is abundantly expressed in lung tissue and controls the transcription of platelet-derived growth factor A (PDGF-A), which plays a pivotal role in alveolar formation, and granulocyte macrophage colony-stimulating factor (GM-CSF), a key regulator of surfactant homeostasis ([@b33-ijn-1-375]). ER-beta, and to a lesser extend ER-alpha, are expressed in lung tumors from both men and women; in a large series of surgically resected NSCLC tumors, ER-beta was detected in 45.8% of cases. Overexpression of ER-beta was significantly more common in tumors from non-smokers (53.5%) than smokers (36.6%, p\<0.004). Among non-smokers, higher ER-beta expression was observed significantly more frequently in female patients (58.3%) than in male patients (40.9%) ([@b51-ijn-1-375]). The complex biological effects mediated by ERs involve communication between many proteins and signaling pathways, including lysosomal vesicle trafficking.

Under the control of estrogen, intracellular trafficking of cathepsin B may be altered in malignant tumors, resulting in the increased secretion of precursor and active forms of the enzyme ([@b35-ijn-1-375]; [@b1-ijn-1-375]; [@b22-ijn-1-375]), its redistribution from perinuclear lysosomes to peripheral vesicles ([@b45-ijn-1-375]), and its association with the cell membrane ([@b47-ijn-1-375]; [@b41-ijn-1-375]; [@b7-ijn-1-375]). Cathepsin B localizes with other proteases at the tumor cell surface in caveolae, mediating cell-surface proteolytic events associated with invasion ([@b38-ijn-1-375]; [@b7-ijn-1-375]). The abundance of cathepsin B in tumor tissue is relevant for the efficient degradation of PPX. The interaction of lung cancer cells and infiltrating immune cells, particularly phagocytic monocytes, can further promote tumor development and metastasis. Homeostasis of human monocytes is regulated by estrogen, and monocytes are known to express both ER-alpha and ER-beta ([@b34-ijn-1-375]). Interestingly, cathepsin X is upregulated in tumor-infiltrating immune cells, particularly in phagocytic monocytes ([@b18-ijn-1-375]).

Summary
=======

Factors limiting the therapeutic index of paclitaxel include low solubility, high systemic exposure, poor pharmacokinetic characteristics, and a lack of selective tumor uptake. The rationale for developing paclitaxel poliglumex (PPX), a macromolecular polymer--drug conjugate, was to improve standard chemotherapy with paclitaxel by overcoming some of these limitations ([Table 4](#t4-ijn-1-375){ref-type="table"}). Tumor pharmacokinetics show that tumor distribution is faster with paclitaxel, but overall tumor exposure is higher with PPX. The available data support a model in which PPX accumulates in tumor tissue through the EPR effect, followed by the cathepsin B-mediated release of paclitaxel.

The cathepsin-mediated release of paclitaxel may have therapeutic implications as cathepsin B is upregulated in malignant cells, particularly during tumor progression. Estrogen may play an important role in lung tumor biology and is a modulator of cathepsin B activity. A possible association between estrogen levels and PPX activity will be further explored in both preclinical and clinical studies.

![Schematic representation of PPX. The structure shown is illustrative of a fragment of the molecule, but specific conjugation sites are not implied. On average there are approximately 10.4 non-conjugated monomer glutamic acid units (a + b) for every molecule conjugated to a paclitaxel molecule (y). The a-poly-L-glutamic degree of polymerization and the number of conjugation sites with paclitaxel are variable within the drug substance's specifications.](ijn-1-375f1){#f1-ijn-1-375}

![Internalization of macromolecules by endocytosis and release of active drug. Macromolecules are internalized through endocytosis. Enzymatic degradation of the polymeric backbone by lysosomal enzymes mediates the release of active drug.](ijn-1-375f2){#f2-ijn-1-375}

![Clinical plasma pharmacokinetics. Plasma samples were collected from patients receiving PPX as a 10- to 30-minute infusion once every 3 weeks. Conjugated and unconjugated paclitaxel were measured by validated HPLC/MS methods. The plasma concentration of conjugated paclitaxel declines biphasically and is characterized by a prolonged distribution phase and an elimination phase with a long terminal half-life.](ijn-1-375f3a){#f3A-ijn-1-375}

![Schematic representation of the plasma pharmacokinetics of paclitaxel vs PPX (unconjugated paclitaxel). Total systemic exposure to PPX (unconjugated of PPX (unconjugated paclitaxel) and standard paclitaxel are similar; however, C~max~ paclitaxel) is lower than equivalent doses of standard paclitaxel.](ijn-1-375f3b){#f3B-ijn-1-375}

![Preclinical tumor pharmacokinetics. To determine the tissue pharmacokinetic profile of PPX, female mice with subcutaneous B16 murine melanomas were given tritium-labeled paclitaxel 40 mg/kg intravenously, either as \[^3^H\]paclitaxel in polyoxyethylated castor oil/ethanol or \[^3^H\]PPX in phasophate buffer. Samples were collected from 0 to 144 hours; the concentration of extractable taxanes was determined by HPLC/MS.](ijn-1-375f4){#f4-ijn-1-375}

![Clinical benefits of reduced myelosupression. A: Percentage of patients with grade 3/4 neutropenia (by treatment cycle) in STELLAR 2. B: Reduced need for supportive measures to manage effects of myelosuppression. \*p\<0.0001; \*\*p\<0.01.](ijn-1-375f5){#f5-ijn-1-375}

###### 

Preclinical tumor pharmacokinetics

                       **C~max~(μg/g)**   **T~max~(h)**   **AUC~last~(μg h/g)**   **MRT (h)**
  -------------------- ------------------ --------------- ----------------------- -------------
  \[^3^H\]PPX                                                                     
    Total taxanes      72.0               4               4547                    51
    Paclitaxel         4.0                72              345                     66
  \[^3^H\]paclitaxel                                                              
    Total taxanes      26.7               1.5             384                     23
    Paclitaxel         22.4               1.5             261                     17

**Notes:** C~max~, highest drug concentration; T~max~, time at which highest drug concentration occurs following administration; AUC~last~, area under the drug concentration-time curve; MRT, mean retention time.

###### 

PPX phase III efficacy summary (no statistically significant differences between the treatment arms were observed in STELLAR 2, 3, and 4)

  **STELLAR 3**    **PPX/Carbo**   **Pac/Carbo**
  ---------------- --------------- ----------------
  N                199             201
  Median OS (mo)   7.8             7.9
  1-yr survival    31%             31%
  2-yr survival    13%             11%
  **STELLAR 4**    **PPX**         **Gem or Vin**
  N                191             190
  Median OS (mo)   7.3             6.6
  1-yr survival    26%             26%
  2-yr survival    15%             13%
  **STELLAR 2**    **PPX**         **Docetaxel**
  N                422             416
  Median OS (mo)   6.9             6.9
  1-yr survival    25%             29%
  2-yr survival    9%              12%

**Abbreviations:** Carbo, carboplatin; gem, gemcitabine; pac, paclitaxel; vin, vinorelbine.

###### 

Hematologic toxicity profile: PPX vs docetaxel (STELLAR 2)

                                                                 **PPX**   **Docetaxel**   **p value**
  -------------------------------------------------------------- --------- --------------- -------------
  Anemia, All                                                    17%       26%             0.002
  Grade 3/4[a](#tfn3-ijn-1-375){ref-type="table-fn"}             5%        4%              0.865
  Neutropenia                                                    21%       44%             \<0.001
  Grade 3/4[a](#tfn3-ijn-1-375){ref-type="table-fn"}             14%       37%             \<0.001
  Thrombocytopenia                                               7%        4%              0.077
  Grade 3/4[a](#tfn3-ijn-1-375){ref-type="table-fn"}             2%        \<1%            0.090
  Febrile Neutropenia[a](#tfn3-ijn-1-375){ref-type="table-fn"}   2%        6%              0.002
  Infection                                                      25%       32%             0.032
  Grade 3/4[a](#tfn3-ijn-1-375){ref-type="table-fn"}             7%        11%             0.088

Reported adverse events.

###### 

Paclitaxel vs PPX

  **Characteristic**   **Paclitaxel**                                     **PPX**
  -------------------- -------------------------------------------------- ------------------------------------------------------------------------------
  Solubility           Requires toxic solubilizing agents                 Water-soluble
  Administration       3- to 24-hr infusion with routine premedications   10- to 20-minute infusion, no routine premedication
  Systemic exposure    Yes                                                Reduced Cmax: gradual paclitaxel release from inactive drug conjugate
  Pharmacokinetics     Short elimination half-life                        Prolonged distribution phase, elimination phase with long terminal half-life
  Tumor selectivity    No                                                 Passive tumor accumulation
